| research round-up
physician counted the hairs in each square before the first treatment and 8 months after the second treatment. immediate and delayed side effects as well as pain scores were recorded. Results: The mean hair count reduction achieved by the diode laser, ipl and ipl+rF was 49.90%, 39.16% and 47.15%, respectively. This study did not show any serious side effects and the number of side effects was minimal. The mean pain scores for the first and second treatments by diode laser, ipl and ipl+rF were 4.65 and 4.58, 2.43 and 2.53, and 3.95 and 4.03, respectively. at the end of the study, a free hair removal treatment for both legs was chosen by patients in the proportion 20 diode laser, 10 ipl and eight ipl+rF. Conclusions: The combination of rF and optical energies proved its safety and efficacy for hair removal, which is comparable with diode lasers and approximately 20% more efficient than ‘pure’ ipl.
ASCORBIC ACID AND N-ACETYL CYSTEINE PREVENT UNCOUPLING OF NITRIC OXIDE SYNTHASE AND INCREASE TOLERANCE TO ISCHEMIA/ REPERFUSION INJURY IN DIABETIC RAT HEART
Okazaki T, Otani H, Shimazu T, Yoshioka K, Fujita M, Iwasaka T. Free Radic Res 2011; 45(10): 1173–83
O
xidaTiVe sTress may cause a lOss of tetrahydrobiopterin (Bh4), a co-factor
of nitric oxide synthase (nOs), decrease the bioavailability of nO and aggravate ischemia/ reperfusion (i/r) injury in diabetic heart. We hypothesized that ascorbic acid (aa) and n-acetyl cysteine (nac) protect the diabetic
heart from i/r injury by increasing Bh4/ dihydrobiopterin (Bh2) ratio and inhibiting uncoupling of nOs. diabetes mellitus was induced in rats by streptozotocin treatment, and the hearts were isolated and perfused. Bh4 and Bh4/Bh2 ratio decreased in the diabetic heart associated with increased production of superoxide and nitrotyrosine (nT). Treatment with aa or nac significantly increased Bh4/Bh2 ratio in the diabetic heart associated with decreased production of superoxide and nT and increased generation of nitrate plus nitrite (nOx). pre-treatment with aa or nac before 30 min ischemia followed by 120 min reperfusion improved left ventricular (lV) function and reduced infarct size in the diabetic but not non-diabetic hearts. The nOs inhibitor, l-name, inhibited the increase in the generation of superoxide, nT and nOx, but aggravated lV function and increased infarct size in the diabetic heart. l-name also abrogated the increase in nOx and improvement of lV function and the infarct size-limiting effect induced by aa or nac in the diabetic heart. These results suggest that aa and nac increase Bh4/Bh2 ratio and prevent nOs uncoupling in the diabetic heart. resultant increase in the bioavailability of nO renders the diabetic heart toleratant to i/r injury.
A SPLIT-FACE STUDY USING BOTULINUM TOXIN TYPE B TO DECREASE FACIAL ERYTHEMA INDEX
Oh Y-J, Lee N-Y, Suh D-H, Koh J-S, Lee S-J, Shin M-K. J Cosmet Laser Ther 2011; 13(5): 243–8
a
reddish TOne in Facial skin is a common concern of patients who suffer
prime-journal.com | October 2011 ❚
from facial flushing. no studies have been conducted to date for evaluation of the effect of botulinum toxin type B (BTx-B) on facial flushing. Materials and method: We evaluated the efficacy of BTx-B for improvement of facial flushing. Fifteen korean subjects who complained of facial flushing were enrolled in this study. patients were randomized to receive BTx-B injections on one side of the face, with the other side receiving saline control injections. changes in skin tone were evaluated using an overall self-assessment and an objective mexameter. Result: after treatment, this mexameter demonstrated significant improvement of erythema at 8 weeks after injections on both sides. however, according to the change in erythema index measures between the two groups, the BTx-B injection side did not show a significant decrease in objective erythema, compared with the control side. subjective satisfaction did not differ between the treated side and the control side. Conclusion: although findings from this study suggest that BTx-B was ineffective in treatment of facial flushing, it is significant that, to the best of our knowledge, this is the first report on an investigator-initiated, randomized, split-face trial for evaluation of efficacy of BTx-B treatment for facial flushing.
51
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84